Protalix BioTherapeutics (PLX) Long-Term Investments (2010 - 2026)

Protalix BioTherapeutics' Long-Term Investments history runs 17 years deep, the most recent figure standing at $589000.0 for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 28.32% year-over-year to $589000.0 in Q1 2026; TTM through Mar 2026 was $589000.0, a 28.32% increase from a year earlier, with the FY2025 full-year figure at $578000.0, up 25.11% from the prior year.
• Long-Term Investments grew to $589000.0 in Q1 2026 per PLX's latest filing, from $578000.0 in the prior quarter.
• Across five years, Long-Term Investments topped out at $2.1 million in Q1 2022 and bottomed at $459000.0 in Q1 2025.
• The 5-year median for Long-Term Investments is $578000.0 (2025), against an average of $896000.0.
• Across the five-year window, Long-Term Investments slumped 58.33% in 2023 and grew 28.32% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $1.3 million in 2022, then tumbled by 58.33% to $528000.0 in 2023, then decreased by 12.5% to $462000.0 in 2024, then grew by 25.11% to $578000.0 in 2025, then advanced by 1.9% to $589000.0 in 2026.
• Per Business Quant, the three latest PLX Long-Term Investments figures stand at $589000.0 (Q1 2026), $578000.0 (Q4 2025), and $549000.0 (Q3 2025).